Pharmaceutical outsourcing is evolving, emphasizing not only capacity but also efficiency, precision, and adaptability. Contract Development and Manufacturing Organizations (CDMOs) are increasingly integrating AI to gain a competitive edge. AI facilitates digital maturity in pharma manufacturing, with tools like digital twins enabling risk-free process simulations that significantly reduce technology transfer timelines. The digital twin market in pharmaceuticals is projected to grow over 20% CAGR through 2030.
Additionally, AI-driven predictive maintenance enhances operational efficacy by anticipating equipment failures, potentially increasing overall equipment effectiveness by 10-20%. The shift towards continuous manufacturing offers greater efficiency and tighter process control, making CDMOs more appealing partners. Companies must address the digital maturity gap by embedding AI into core operations, ensuring compliance and workforce readiness. As sponsor expectations shift, CDMOs that leverage AI technologies effectively will position themselves not just as service providers but as strategic partners shaping impactful outcomes in drug development and manufacturing.
Source link
